The Group, Which Makes Chemicals Used in Products From Animal Feed to Pfizer and BioNTech's Covid Vaccine, Announced up to 2,000 Job Cuts by 2026 Dec 13 (Reuters) - Germany's Evonik Evkn.de Plans to Restructure Its Business Lines Into Two Segments, It Said on Friday.
12月13日（路透社）- 德国Evonik Evkn.de 该公司周五表示计划将其业务线重组为两个业务部门。
From April 1, the Group Will Focus on Its Two Core Operating Businesses: Custom Solutions and Advanced Technologies.
从4月1日起，该集团将专注于两个核心运营业务：定制解决方案和爱文思控股。
Evonik's Custom Solutions Segment Includes Additives for Paints and Coatings, as Well as Products for the Cosmetics and Pharmaceutical Industries. Its Advanced Technologies Segment Focuses Mostly on High Performance Polymers and Hydrogen Peroxide Production.
Evonik的定制解决方案部门包括涂料和涂层的添加剂，以及化妆品和药品行业的产品。其爱文思控股部门主要专注于高性能聚合物和过氧化氢生产。
By the End of 2026, Evonik Plans to Reduce the Number of Management Levels From an Average of 10 to a Maximum of Six Across the Group, in Line With Its "Tailor Made" Reorganisation Programme.
到2026年底，Evonik计划将管理层级数从平均10个减少到最多6个，以配合其“量身定制”重组项目。
The Group, Which Makes Chemicals Used in Products From Animal Feed to Pfizer and BioNTech's Covid Vaccine, Announced up to 2,000 Job Cuts by 2026 In March With the Goal of Reducing Costs by 400 Million Euros ($437.3 Million) Annually.
该集团生产的化学品用于从动物饲料到辉瑞和BioNTech的Covid生物-疫苗等产品，宣布到2026年将裁员多达2000人。 在三月 为了每年减少40000万欧元（约合43730万）的成本。
Germany's Chemicals Industry Suffered Heavily Throughout 2023 Due to High Production Costs and Weak Demand Amid Rising Inflation. Initial Signs of Recovery in the First Quarter of This Year Have Begun to Fade Away.
由于高生产成本和通货膨胀加剧，德国的化学品行业在2023年遭受了重大损失。 今年第一季度初步复苏的迹象已经开始消退。
(Reporting by Anastasiia Kozlova and Amir Orusov, Editing by Friederike Heine)
（报道：Anastasiia Kozlova 和 Amir Orusov，编辑：Friederike Heine）
((Anastasiia.kozlova@Thomsonreuters.com; Amir.orusov@Thomsonreuters.com))
（（Anastasiia.kozlova@Thomsonreuters.com； Amir.orusov@Thomsonreuters.com））
